Nephros Issues 2022 Shareholder Letter
SOUTH ORANGE, NJ, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology...
News
Auxly Maintains Top Position in 2.0, Dominates Vape Sales and Grows National Market Share Through 1.0 Expansion in 2021
Headset data confirms Auxly almost doubled overall market share, ending the year as the #5 LP in Canada and continues...
Vitalhub Announces Multi-Year Licensing Agreement with Stafford and Stoke-on-Trent Integrated Care Systems
TORONTO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce a...
Quipt Provides Bi-Weekly Status Update
CINCINNATI, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based...
Achilles Therapeutics Provides Business Update and Outlook for 2022
LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell...
Congenica Expands its Clinical Consulting Services
Congenica Expands its Clinical Consulting Services Cambridge, United Kingdom – 13 January 2022 - Congenica, the digital health company enabling...
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes Strategy focuses on developing and commercializing...
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
– Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated...
Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study
Positive interim biomarker data supports specific immune signature induced by IMCY-0098 and effect on potentially pathogenic T cells Enrollment on...
First Wave BioPharma Provides Update on Adrulipase (FW-EPI) Clinical Program
Company filed two provisional patent applications for new enteric granule formulation of adrulipase and for related nutritional indications in new...
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC
Conference call and live audio webcast scheduled for today at 8:30 a.m. ESTTransformative acquisition significantly expands Salarius’ oncology pipeline into...
PacBio Names Lara Toerien as Vice President and General Manager for the Americas
Industry Veteran Will Lead Company’s Commercial Growth Strategy in Americas RegionMENLO PARK, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- PacBio...
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.
Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program...
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC...
Tiziana Life Sciences Announces Death of Director
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies...
VYNE Therapeutics Divests Topical Minocycline Assets
Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic...
Acutus Medical’s Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium
CARLSBAD, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on...
Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea
MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on...
Global Wholehealth Partners Corporation Declares Special Common Stock Dividend
San Clemente, CA, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- On January 13, 2022, Global Wholehealth Partners Corporation...
Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore
Clinical trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration...
